NewAmsterdam Pharma Company N.V. Operating Income
NewAmsterdam Pharma Company N.V. (NAMS) reported Operating Income of -$64.86 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-05
- NewAmsterdam Pharma Company N.V. operating income (loss) for the quarter ending 2026-06-30 was -$64.86M.
- NewAmsterdam Pharma Company N.V. operating income (loss) for the quarter ending 2026-03-31 was -$58.42M.
- NewAmsterdam Pharma Company N.V. operating income (loss) for the quarter ending 2025-12-31 was -$65.98M.
- NewAmsterdam Pharma Company N.V. operating income (loss) for the quarter ending 2025-09-30 was -$55.14M.
- NewAmsterdam Pharma Company N.V. operating income (loss) for fiscal 2025 was -$225.68M.
- NewAmsterdam Pharma Company N.V. operating income (loss) for fiscal 2024 was -$176.29M.
- NewAmsterdam Pharma Company N.V. operating income (loss) for fiscal 2023 was -$182.97M.
- NewAmsterdam Pharma Company N.V. operating income (loss) for fiscal 2022 was -$3.56M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$64.86M 10-Q · filed 2026-08-05 | -$123.28M 10-Q · filed 2026-08-05 | -$189.26M derived: sum of 3 quarters · filed 2026-08-05 | -$244.41M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$58.42M 10-Q · filed 2026-05-07 | -$124.40M derived: sum of 2 quarters · filed 2026-05-07 | -$179.54M derived: sum of 3 quarters · filed 2026-05-07 | -$215.18M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$65.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | -$121.12M derived: sum of 2 quarters · filed 2026-02-18 | -$156.76M derived: sum of 3 quarters · filed 2026-08-05 | -$225.68M 10-K · filed 2026-02-18 |
| 2025-09-30 | -$55.14M 10-Q · filed 2025-11-05 | -$90.78M derived: sum of 2 quarters · filed 2026-08-05 | -$159.70M 10-Q · filed 2025-11-05 | -$202.93M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$35.63M 10-Q · filed 2026-08-05 | -$104.56M 10-Q · filed 2026-08-05 | -$147.79M derived: sum of 3 quarters · filed 2026-08-05 | -$172.79M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$68.92M 10-Q · filed 2026-05-07 | -$112.15M derived: sum of 2 quarters · filed 2026-05-07 | -$137.16M derived: sum of 3 quarters · filed 2026-05-07 | -$189.73M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$43.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | -$68.23M derived: sum of 2 quarters · filed 2026-02-18 | -$120.81M derived: sum of 3 quarters · filed 2026-02-18 | -$176.29M 10-K · filed 2026-02-18 |
| 2024-09-30 | -$25.00M 10-Q · filed 2025-11-05 | -$77.58M derived: sum of 2 quarters · filed 2025-11-05 | -$133.06M 10-Q · filed 2025-11-05 | -$184.13M derived: sum of 4 quarters · filed 2026-02-18 |
| 2024-06-30 | -$52.58M 10-Q · filed 2025-08-06 | -$108.06M 10-Q · filed 2025-08-06 | -$159.13M derived: sum of 3 quarters · filed 2026-02-18 | -$208.69M derived: sum of 4 quarters · filed 2026-02-18 |
| 2024-03-31 | -$55.48M 10-Q · filed 2025-05-08 | -$106.56M derived: sum of 2 quarters · filed 2026-02-18 | -$156.11M derived: sum of 3 quarters · filed 2026-02-18 | -$198.60M derived: sum of 4 quarters · filed 2026-02-18 |
| 2023-12-31 | -$51.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | -$100.63M derived: sum of 2 quarters · filed 2026-02-18 | -$143.11M derived: sum of 3 quarters · filed 2026-02-18 | -$182.97M 10-K · filed 2026-02-18 |
| 2023-09-30 | -$49.56M 10-Q · filed 2024-11-06 | -$92.04M derived: sum of 2 quarters · filed 2024-11-06 | -$131.89M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | -$42.48M 10-Q · filed 2024-08-07 | -$82.33M 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | -$39.85M 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | -$3.56M 10-K · filed 2025-02-26 | |||
| 2021-12-31 | -$34.98M 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |